Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

MLA

Mieke Van Hemelrijck, et al. “Determinants of 5-Year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-Line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-Real 5Y Global Registry.” Journal for ImmunoTherapy of Cancer, vol. 13, no. 2, Feb. 2025. EBSCOhost, https://doi.org/10.1136/jitc-2024-010674.

APA

Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, … Taher Abu Hejleh. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer, 13(2). https://doi.org/10.1136/jitc-2024-010674

Chicago

Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, et al. 2025. “Determinants of 5-Year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-Line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-Real 5Y Global Registry.” Journal for ImmunoTherapy of Cancer 13 (2). doi:10.1136/jitc-2024-010674.